Cetuximab
MedicationWikipedia
10
MENTIONS
8
EPISODES
8
PODCASTS
Search complete. 10 mentions across 8 episodes found for "Cetuximab".
Oct 12, 2026
Jannese TorresHOST
Yeah, I actually worked for a company called ImClone Systems who's now, who was acquired by Eli Lilly like back in, I think, 2008.
Jannese TorresHOST
And their first drug was, um, around a, a drug called Erbitux, which was for non-small cell lung cancer.
Jannese TorresHOST
So yeah, we did a lot of, a lot of research with that.
Jannese TorresHOST
And so it's wild to see like full circle how, you know, the work that you do can impact somebody you don't even realize.
John KuceraGUEST
Every person makes anti-Gal IgA, IgG, and IgM antibodies.
John KuceraGUEST
IgE sensitization, which comes from the Lone Star tick, the Ixodes tick, or Cetuximab, is what results in the syndrome that we describe as alpha-gal syndrome, again, in a subset of patients who are seropositive.
John KuceraGUEST
And so for, you know, the lay person, that means that this reaction is occurring in every person that's getting a bioprosthetic aortic valve replacement.
Scott ComminsHOST
Not just people that have been bitten by the tick.
Samuel KlempnerGUEST
Multiple drugs, but this is the approved drug, Zolbituximab.
Samuel KlempnerGUEST
Essentially, this is a naked antibody, kind of like Cetuximab, Panetumumab.
Samuel KlempnerGUEST
It binds the surface target, in this case, Clawden 18.2. You recruit a bunch of secondary effector cells, NK cells, et cetera, myeloid-associated cells, and you get secondary T-cell activation and ADCC.
Samuel KlempnerGUEST
And this is how many antibodies works.
Samuel KlempnerGUEST
multiple drugs, but this is the approved drug, Zolbituximab.
Samuel KlempnerGUEST
Essentially, this is a naked antibody, kind of like Cetuximab, Panetumumab.
Samuel KlempnerGUEST
It binds the surface target, in this case, Clawden 18.2. You recruit a bunch of secondary effector cells, NK cells, et cetera, myeloid-associated cells, and you get secondary T-cell activation and ADCC.
Samuel KlempnerGUEST
And this is how many antibodies works.
Samuel KlempnerGUEST
multiple drugs, but this is the approved drug, Zolbituximab.
Samuel KlempnerGUEST
Essentially, this is a naked antibody, kind of like Cetuximab, Panetumumab.
Samuel KlempnerGUEST
It binds the surface target, in this case, Clawden 18.2. You recruit a bunch of secondary effector cells, NK cells, et cetera, myeloid-associated cells, and you get secondary T-cell activation and ADCC.
Samuel KlempnerGUEST
And this is how many antibodies works.
Mike HuckmanGUEST
Started covering big pharma.
Mike HuckmanGUEST
And then Avastin and Erbitux were bursting onto the radar screen in a big, big way at that time.
Mike HuckmanGUEST
And Erbitux for lots of other reasons too.
Mike HuckmanGUEST
Inclined systems.
Mike HuckmanGUEST
So then I moved my way into biotech as well.
Ran NussbaumGUEST
This guy, Sam Waxell, is responsible for Inclon.
Ran NussbaumGUEST
Inclon is the company that brought Erbitox to the world.
Litan YahavHOST
Erbitox is a
Ran NussbaumGUEST
$7 billion drug for CLC, for colon cancer.
Ran NussbaumGUEST
He created, after that, Cadman, that created a drug for GVHD and sold to Novartis, to Sanofi.
Ebru DavidsonGUEST
Look, although I have to say we recognize that this was a small early stage study and that injected tumor response is not directly interchangeable with conventional sort of patient level response rates.
Ebru DavidsonGUEST
But to answer your question, how significant is that number in the context of what's currently available? So current leading treatments, again, is Cetuximab, which is sitting around 32% ORR.
Andrew MusgraveHOST
And six tumours achieved complete ablation and none recurred during the time patients were on study.
Andrew MusgraveHOST
What does that durability signal tell you about TT's mechanism and how confident are you that it will hold up over a longer period?